Journey Medical Corporation Announces Data from Bioavailability Study of DFD29 Minocycline Hydrochloride Modified Release Capsules 40 mg vs Solodyn Minocycline Hydrochloride ExtendedRelease Tablets 105 mg

SCOTTSDALE, Ariz., Oct. 20, 2023 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced data from a comparative bioavailability (bridging) study of DFD-29 (Minocycline…Read More